CYMABAY THERAPEUTICS INC (CBAY) Stock News
NASDAQ:CBAY - Nasdaq - US23257D1037 - Common Stock - Currency: USD
CBAY Latest News, Press Relases and Analysis
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a third of revenue from oncology by decade's end.
Mentions: GILD
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. ...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
CymaBay Therapeutics GAAP EPS of -$0.35 misses by $0.04 (NASDAQ:CBAY)
CymaBay Therapeutics reports Q4 2023 financial results, with GAAP EPS missing estimates.
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted...
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
Inventiva stock drops after delay in Phase 3 NASH trial
Inventiva (IVA) stock plummeted as it announced a delay in its Phase 3 trial for NASH candidate lanifibranor due to an adverse event. Read more here.
Liver disease drug developers rise after Gilead-CymaBay deal (NASDAQ:GILD)
Gilead's (GILD) acquisition of CymaBay Therapeutics CBAY) boosts liver disease-focused drug developers, leading to notable gains in their stock prices. Read more here.
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
/PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.
Mentions: GILD
Gilead to acquire CymaBay for $32.50/share in cash (NASDAQ:GILD)
Gilead Sciences to acquire CymaBay Therapeutics for $4.3B, adding seladelpar to its liver portfolio.
Mentions: GILD
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other...
Gilead to Buy Liver Drugmaker for $4.3 Billion Equity Value
Gilead Sciences Inc. agreed to purchase CymaBay Therapeutics Inc., a developer of an experimental liver disease drug, for $4.3 billion in equity value.
Mentions: GILD
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Mentions: GILD
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies...
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
The company is working on the first treatment that could make a difference in the itching associated with a liver disease.
Mentions: GNFT